|
Video: What is a Stock Split?
|
|
Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company. Co.'s targeted radiotherapies combine the cell-killing ability of radiation via a radioisotope payload with a targeting agent to deliver radiation in a precise manner inside the body to specific targeted cells. Co.'s Iomab-B and Actimab-A product candidates are focused on addressing the medical needs in relapsed or refractory acute myeloid leukemia (AML) in a complementary manner and are directed at different parts of the patient journey. Iomab-B is a targeted radiotherapy consisting of apamistamab. Actimab-A (225Ac-lintuzumab satetraxetan) program is focused on developing combinations with other AML treatment regimens. According to our ATNM split history records, Actinium Pharmaceuticals has had 1 split. | |
|
Actinium Pharmaceuticals (ATNM) has 1 split in our ATNM split history database. The split for ATNM took place on August 11, 2020. This was a 1 for 30 reverse split, meaning for each 30 shares of ATNM owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 33.3333333333333 share position following the split.
When a company such as Actinium Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ATNM split history from start to finish, an original position size of 1000 shares would have turned into 33.3333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Actinium Pharmaceuticals shares, starting with a $10,000 purchase of ATNM, presented on a split-history-adjusted basis factoring in the complete ATNM split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/22/2014 |
|
End date: |
04/19/2024 |
|
Start price/share: |
$377.70 |
|
End price/share: |
$6.85 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-98.19% |
|
Average Annual Total Return: |
-33.03% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$181.47 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
08/11/2020 | 1 for 30 |
|
|